Track topics on Twitter Track topics that are important to you
Joe Dupere, CEO at Rexgenero, reveals to Mike Ward during Biotech Showcase 2019 the four-year-old UK biotech’s plans.
At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona London, UK – 24 April 2019 – Rexgenero, a regenerative medicine ...
At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona Rexgenero, a regenerative medicine company pioneering the development...
Paul Peter Tak recently defected from big pharma to East Coast venture firm Flagship Pioneering. He described the appeal of...
Speaking on the sidelines of Biotech Showcase 2019, Dan Gooding, CEO of Nuformix, explains to Mike Ward how the UK...
Julien Pham, President and COO of Genprex, describes to Mike Ward how the company is using a technology platform to...
Rexgenero is a clinical-stage regenerative medicine company developing innovative cell-based therapies targeting serious diseases with unmet medical needs.
We have published hundreds of Rexgenero news stories on BioPortfolio along with dozens of Rexgenero Clinical Trials and PubMed Articles about Rexgenero for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Rexgenero Companies in our database. You can also find out about relevant Rexgenero Drugs and Medications on this site too.